相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。TERT structural rearrangements in metastatic pheochromocytomas
Trisha Dwight et al.
ENDOCRINE-RELATED CANCER (2018)
Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma
Richard B. Noto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center
Henrik Falhammar et al.
ENDOCRINE CONNECTIONS (2018)
Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma
Katarina Kluckova et al.
CELL AND TISSUE RESEARCH (2018)
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities
Emily K. Kleczko et al.
MOLECULAR CANCER (2018)
Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma
Guillaume Gravel et al.
ENDOCRINE (2018)
Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma
Alejandro Roman-Gonzalez et al.
ANNALS OF SURGERY (2018)
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
S. Chouaib et al.
ONCOGENE (2017)
The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids
Vanessa D'Antongiovanni et al.
ENDOCRINE-RELATED CANCER (2017)
New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas
Rodrigo Almeida Toledo
ENDOCRINE-RELATED CANCER (2017)
Feasibility of a wait-and-scan period as initial management strategy for head and neck paraganglioma
Thijs T. G. Jansen et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2017)
Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review
Ruth T. Casey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
Grace Kong et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas
Konstantinos Nastos et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
Whole-genome landscape of pancreatic neuroendocrine tumours
Aldo Scarpa et al.
NATURE (2017)
Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials
Alejandro Roman-Gonzalez et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2017)
Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress
Paola Jimenez et al.
CURRENT ONCOLOGY REPORTS (2017)
Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients
Julien Hadoux et al.
HORMONES & CANCER (2017)
Head and Neck Paragangliomas: A Two-Decade Institutional Experience and Algorithm for Management
Joshua D. Smith et al.
LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY (2017)
Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours
Alfred King-yin Lam
ENDOCRINE PATHOLOGY (2017)
Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma
Sina Jasim et al.
ENDOCRINE (2017)
Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
Rodrigo A. Toledo et al.
CLINICAL CANCER RESEARCH (2016)
Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
Sara Labiano et al.
ONCOIMMUNOLOGY (2016)
Identification of Targets of the HIF-1 Inhibitor IDF-11774 Using Alkyne-Conjugated Photoaffinity Probes
Hyun Seung Ban et al.
BIOCONJUGATE CHEMISTRY (2016)
A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer
Stephen M. Hatfield et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Cabozantinib: A Review in Advanced Renal Cell Carcinoma
Zaina T. Al-Salama et al.
DRUGS (2016)
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Jose Manuel Ruiz-Morales et al.
EUROPEAN JOURNAL OF CANCER (2016)
HRAS mutation prevalence and associated expression patterns in pheochromocytoma
Adam Stenman et al.
GENES CHROMOSOMES & CANCER (2016)
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Matthew Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
From Nf1 to Sdhb knockout: Successes and failures in the quest for animal models of pheochromocytoma
Charlotte Lepoutre-Lussey et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
Targeting renal cell carcinoma with a HIF-2 antagonist
Wenfang Chen et al.
NATURE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sunitinib: the antiangiogenic effects and beyond
Zhonglin Hao et al.
ONCOTARGETS AND THERAPY (2016)
ATRX driver mutation in a composite malignant pheochromocytoma
Inaki Comino-Mendez et al.
CANCER GENETICS (2016)
Heritable Cancer Syndromes Related to the Hypoxia Pathway
John Clark Henegan et al.
FRONTIERS IN ONCOLOGY (2016)
Axitinib: A Review in Advanced Renal Cell Carcinoma
Gillian M. Keating
DRUGS (2015)
Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma
Sonali Thosani et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
Lauren Fishbein et al.
NATURE COMMUNICATIONS (2015)
Deciphering the molecular basis of invasiveness in Sdhb-deficient cells
Celine Loriot et al.
ONCOTARGET (2015)
Lower cranial nerves function after surgical treatment of Fisch Class C and D tympanojugular paragangliomas
Andrea Bacciu et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2015)
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine
Judith Favier et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma
Teik Hin Tan et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Subhajit Roy et al.
Anti-Cancer Agents in Medicinal Chemistry (2014)
I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis
L. T. van Hulsteijn et al.
CLINICAL ENDOCRINOLOGY (2014)
Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis
N. D. Niemeijer et al.
CLINICAL ENDOCRINOLOGY (2014)
Cabozantinib: A Review of Its Use in Patients with Medullary Thyroid Cancer
Sheridan M. Hoy
DRUGS (2014)
THERAPY OF ENDOCRINE DISEASE Treatment of malignant pheochromocytoma and paraganglioma
Eric Baudin et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
Luis Jaime Castro-Vega et al.
HUMAN MOLECULAR GENETICS (2014)
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
Julien Hadoux et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
H-RAS Mutations Are Restricted to Sporadic Pheochromocytomas Lacking Specific Clinical or Pathological Features: Data From a Multi-Institutional Series
Lindsey Oudijk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
Jacques W. M. Lenders et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Correlation Between In Vivo 18F-FDG PET and Immunohistochemical Markers of Glucose Uptake and Metabolism in Pheochromocytoma and Paraganglioma
Anouk van Berkel et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Impact of Surgical Resection for Subdiaphragmatic Paragangliomas
Shabirhusain S. Abadin et al.
WORLD JOURNAL OF SURGERY (2014)
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Patricia L. M. Dahia
NATURE REVIEWS CANCER (2014)
SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma
Eric Letouze et al.
CANCER CELL (2013)
In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas
Rodrigo A. Toledo et al.
ENDOCRINE-RELATED CANCER (2013)
The Characterization of Pheochromocytoma and Its Impact on Overall Survival in Multiple Endocrine Neoplasia Type 2
Sonali Thosani et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Bone Metastases and Skeletal-Related Events in Patients With Malignant Pheochromocytoma and Sympathetic Paraganglioma
Montserrat Ayala-Ramirez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Long-Term Outcomes of Surgical Treatment for Hereditary Pheochromocytoma
Elizabeth G. Grubbs et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma
Camilo Jimenez et al.
CURRENT ONCOLOGY REPORTS (2013)
Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor
J. Keith Killian et al.
CANCER DISCOVERY (2013)
Combination Chemotherapy with Cyclophosphamide, Vincristine, and Dacarbazine in Patients with Malignant Pheochromocytoma and Paraganglioma
Akiyo Tanabe et al.
HORMONES & CANCER (2013)
Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas Insights from the largest single-institutional experience
Montserrat Ayala-Ramirez et al.
CANCER (2012)
A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma
J. B. Maurice et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Metastatic Pheochromocytoma and Paraganglioma: Focus on Therapeutics
P. -F. Plouin et al.
HORMONE AND METABOLIC RESEARCH (2012)
Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma
Nelly Burnichon et al.
HUMAN MOLECULAR GENETICS (2012)
Epithelial to Mesenchymal Transition Is Activated in Metastatic Pheochromocytomas and Paragangliomas Caused by SDHB Gene Mutations
Celine Loriot et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas
Montserrat Ayala-Ramirez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Concise Drug Review: Pazopanib and Axitinib
Robin M. J. M. van Geel et al.
ONCOLOGIST (2012)
Cancer Immunotherapy
Robert O. Dillman
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators
Montserrat Ayala-Ramirez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Radioiodinated Metaiodobenzylguanidine (MIBG): Radiochemistry, Biology, and Pharmacology
Shankar Vallabhajosula et al.
SEMINARS IN NUCLEAR MEDICINE (2011)
Changing Paradigms in the Treatment of Malignant Pheochromocytoma
Raymon H. Grogan et al.
CANCER CONTROL (2011)
Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center
Auryan Szalat et al.
ENDOCRINE (2011)
Comparison of High-Specific-Activity Ultratrace 123/131I-MIBG and Carrier-Added 123/131I-MIBG on Efficacy, Pharmacokinetics, and Tissue Distribution
John A. Barrett et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Mechanisms of resistance to antiangiogenesis therapy
Faisal Azam et al.
EUROPEAN JOURNAL OF CANCER (2010)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
A. Singh et al.
ONCOGENE (2010)
Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score
David Wu et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Malignant Pheochromocytomas and Paragangliomas: Molecular Signaling Pathways and Emerging Therapies
L. Santarpia et al.
HORMONE AND METABOLIC RESEARCH (2009)
Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma
Sara Gonias et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Treatment of Malignant Pheochromocytoma/Paraganglioma With Cyclophosphamide, Vincristine, and Dacarbazine Recommendation From a 22-Year Follow-up of 18 Patients
Hui Huang et al.
CANCER (2008)
123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas:: CT and MRI correlation
Kunwar S. S. Bhatia et al.
CLINICAL ENDOCRINOLOGY (2008)
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma
Henri J. L. M. Timmers et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Telomeres and human disease: Ageing, cancer and beyond
MA Blasco
NATURE REVIEWS GENETICS (2005)
A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas
PLM Dahia et al.
PLOS GENETICS (2005)
The diagnosis and medical management of advanced neuroendocrine tumors
GA Kaltsas et al.
ENDOCRINE REVIEWS (2004)
Somatostatin receptor subtypes in human pheochromocytoma: Subcellular expression pattern and functional relevance for octreotide scintigraphy
J Mundschenk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)
分享论文
